Erratum to “Diagnosis and treatment of chronic lymphocytic leukemia: Recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia” [Rev Bras Hematol Hemoter. 2016;38(4):346–357]

In the article “Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia”, published in Rev Bras Hematol Hemoter 2016;38:346–57, please consider the following correction:

2) Relapsed first-line treatment:

• a)Progress after 24 months: repeat first-line treatment (add an anti-CD20 antibody if not used in the first-line treatment)
• b)
  Progress within 24 months:

  • -
    ‘Go-go’ patients: ibrutinib

    • •
      Alternative options: venetoclax, alemtuzumab with or without methylprednisolone, rituximab with or without high-dose methylprednisolone, allogeneic HCST, bendamustine plus rituximab
  • -
    ‘Slow-go’ patients: ibrutinib

    • •
      Alternative options: idelalisib plus rituximab, alemtuzumab with or without methylprednisolone, rituximab with or without high-dose methylprednisolone bendamustine plus rituximab, FCR-lite